Talaris Therapeutics : Costs Associated with Exit/Disposal -

8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT


Pursuant to... | April 14, 2023

Related Keywords

Delaware , United States , Massachusetts , Washington , Worcester , Scott Requadt , Mary Kay Fenton , Andrew Farnsworth , Nancy Krieger , Michael Zdanowski , Talaris Therapeutics Inc , Company Board Of Directors , Company Annual Report On Form , Exchange Commission , Securities Exchange , Commission File Number , Securities Exchange Act , Its Charter , Principal Executive Offices , Zip Code , Telephone Number , Including Area Code , Former Name , Former Address , Changed Since Last Report , Securities Act , Exchange Act , Talaris Therapeutics , April Reduction , Certain Officers , Compensatory Arrangements , Chief Executive Officer , Chief Medical Officer , Chief Technology Officer , Chief Human Resources Officer , Restated Executive Severance , Control Plan , Annual Report , Chief Financial Officer , Retention Agreement , Strategic Transaction , Mary Kay , Page Interactive Data File , Current Report , Private Securities Litigation Reform Act , Chief Executive , Nc Stock Exchange , News , Information , Press Release , United , Securities , End , Exchange , Form , Current , Ursuant Tals Us87410c1045 ,